NCIC CTG IND.122: a phase I/II pharmacokinetics (PK) and pharmacodynamic (PD) study of zd1839 (iressa ‘TM’). Final phase I results and preliminary phase II results of ZD1839 (750 mg/day) in patients (pts) with colorectal cancer
Year: 2001
Type: article
Source: European Journal of Cancer
Authors: G. Goss, H. Hirte, G. Batist, W. Miller, D. Stewart, S. Matthews, L. Seymour
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W1985016786